Hepatocellular carcinoma or HCC is the most commonly observed form of liver cancer and the fourth leading cause of ...

BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a leader in antibody reactome profiling, announces the launch of HuSIGHT-Total™, ...

Significant associations were found between certain autoantibodies and neuropsychiatric manifestations of SLE.

Tremfya is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis.

In what could be a preview of an even greater disease burden for those workers in the artificial stone benchtop industry, ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Johnson & Johnson (NYSE: JNJ) has announced the FDA‘s approval of TREMFYA® (guselkumab) for adults with moderately to ...

Johnson & Johnson has announced that the US FDA has approved TREMFYA for the treatment of active ulcerative colitis (UC).

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

Although the drug delivered positive results - reducing autoantibody IgG levels with no severe side effects - the early data fell short of expectations. We think investors set their sights too high ...

The study, which will serve “as a guide for rapid diagnosis”, provides valuable information for the medical community, in ...